Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group

This study failed to demonstrate a survival benefit of the addition of celecoxib to palliative chemotherapy.